Covetrus Announces Appointment of Matthew Leonard as Executive Vice President, President North America and Global Supply Chain Officer

March 26, 2019 Off By BusinessWire

Leonard Brings Significant Expertise in Technology, Procurement and
Supply Chain

PORTLAND, Maine–(BUSINESS WIRE)–Covetrus (NASDAQ: CVET), a global leader in animal-health technology and
services, announced today that Matthew Leonard has been named Executive
Vice President, President North America and Global Supply Chain Officer
effective April 8, 2019. In his role, Leonard will lead the North
American customer operations business in Dublin, Ohio and be responsible
for leading the company’s global manufacturer relationships. Leonard
will report directly to Chief Executive Officer Benjamin Shaw and will
serve on the company’s executive leadership team.

“Matt’s extensive leadership and experience in healthcare services,
manufacturer partnerships and global pharmaceutical supply chain will be
a significant asset to our organization as we execute on our mission as
a new company,” said Shaw. “Driving a differentiated value proposition
for our North American veterinary practice customers and coordinating
our scope of capabilities globally will enable us to capitalize on the
significant number of growth opportunities we have in front of us.”

Leonard joins Covetrus from CVS Health after more than two decades of
service, most recently as EVP of Pharmaceutical Contracting, Purchasing
& Managed Care. Leonard was also President and Chairman of the Board of
Red Oak Sourcing, LLC, the largest generic drug purchasing entity in the
United States, where he oversaw all aspects of CVS Health’s generic
sourcing venture with Cardinal Health. During his tenure, Leonard led
strategy and operations for CVS’ pharmaceutical purchasing program and
was responsible for the company’s relationships with pharmaceutical
manufacturers and wholesalers. Leonard also architected and executed
strategies to drive operational excellence throughout the supply chain,
including purchasing efficiencies tied to numerous M&A transactions CVS
Health completed over the last two decades.

“I am excited by the future of Covetrus as we seek to unlock significant
value to not only our veterinary practice customers and their clients,
but our manufacturer partners across the globe,” said Leonard. “We have
an incredible opportunity here in North America, and I am looking
forward to joining this exceptional team and finding new ways to drive
enhanced growth and operational excellence across the organization.”

Leonard received a Bachelor of Science in Pharmacy from the University
of Rhode Island and is a registered pharmacist.

About Covetrus
Covetrus is a global animal-health technology
and services company dedicated to empowering veterinary practice
partners to drive improved health and financial outcomes. We’re bringing
together products, services, and technology into a single platform that
connects our customers to the solutions and insights they need to work
best. Our passion for the well-being of animals and those who care for
them drives us to advance the world of veterinary medicine. Covetrus is
headquartered in Portland, Maine, with more than 5,000 employees,
serving over 100,000 customers around the globe. For more information
about Covetrus visit https://www.covetrus.com/.

Forward-Looking Statements
This press release contains
certain statements that are forward-looking within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended, and that involve
risks and uncertainties, including statements about our future financial
and operating results, plans, objectives, expectations, intentions, and
hiring of new executives and employees. We may, in some cases use terms
such as “predicts,” “believes,” “potential,” “continue,” “anticipates,”
“estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,”
“likely,” “will,” “should” or other words that convey uncertainty of the
future events or outcomes to identify these forward-looking statements.
Such statements are subject to numerous risks and uncertainties,
including but not limited to, risks associated with the ability to
successfully integrate operations and employees; the ability to realize
anticipated benefits and synergies of the transaction that created
Covetrus; the potential impact of the consummation of the transaction on
relationships, including with employees, customers and competitors; the
ability to retain key personnel; the ability to achieve performance
targets; changes in financial markets, interest rates and foreign
currency exchange rates, and those additional risks and factors
discussed in our Registration Statement on Form S-1 filed on February 7,
2019, including those discussed under the heading “Risk Factors.” Our
forward-looking statements are based on current beliefs and expectations
of our management team and, except as required by law, we undertake no
obligations to make any revisions to the forward-looking statements
contained in this release or to update them to reflect events or
circumstances occurring after the date of this release, whether as a
result of new information, future developments or otherwise. Investors
are cautioned not to place undue reliance on these forward-looking
statements.